Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)
Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease
Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease
Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…Gut dysbiosis in Parkinson’s disease with motor complications
Objective: We aimed to identify gut dysbiosis in Parkinson's disease patients with motor complications. Background: Recently, several evidences suggest that the gut microbiota is associated…Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project
Objective: To characterize patients with early versus later levodopa exposure, defining “early” as within 2 years of Parkinson’s disease (PD) diagnosis, and to determine whether…Determination of 5-HT3 receptor levels with [3H]-GR 65630 binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia
Objective: To determine the distribution of serotonin type 3 (5-HT3) receptors in brain areas implicated in L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat…Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Slow wave activity as a marker of levodopa induced dyskinesia
Objective: To assess the role of slow wave activity during slow wave sleep (SWS-SWA) as a marker of levodopa induced dyskinesia (LID) development in Parkinson's…The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with bitopertin on dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 49
- Next Page »